** Shares of gene therapy developer Rocket Pharmaceuticals RCKT.O fall 3.9% to $12.98 premarket
** RCKT sold 13.2 mln shares in an upsized public offering at $12.50/shr for gross proceeds of $165 mln
** Offering size was boosted from the $150 mln worth of shares announced on Tuesday, priced at a 7.5% discount to stock's last close of $13.51
** Additionally, on Tuesday, life sciences investment firm RTW had agreed to purchase pre-funded warrants representing the right to purchase $5 mln worth of RCKT shares in a concurrent private placement
** Morgan Stanley, Leerink Partners and Cantor were the joint book-running managers for the offering
** RCKT had 91.2 mln outstanding shares as of Sept. 30, according to an SEC filing, giving it a $1.23 bln market capitalization as of most recent closing price
** As of last close, RCKT shares down 54.9% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。